VE 4840
Alternative Names: VE-4840Latest Information Update: 25 Jan 2023
At a glance
- Originator Verseon
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy
Most Recent Events
- 07 Sep 2022 Verseon has patent protection for plasma kallikrein inhibitors for diabetic nephropathy in Europe, USA, Mexico, Israel, and Australia
- 05 Aug 2021 Verseon intends to submit IND application for VE-4840
- 05 Aug 2021 Pharmacodynamics data from preclinical studies in Diabetic retinopathy released by Verseon